Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Nivolumab may be beneficial for recurrent or metastatic cervical cancer

Publish date:: September 16, 2019

Key clinical point: Nivolumab may have some potential for treating recurrent and metastatic gynecologic cancers.

Major finding: 26.3% of patients with cervical cancer and 20% with vaginal/vulvar cancers experienced an objective response.

Study details: A cohort within the phase 1/2 CheckMate 358 trial for patients with virus-associated tumors.

Disclosures: Bristol-Myers Squibb funded the study. Several of Dr. Naumann’s associates reported relationships with the company and four others are employed by Bristol-Myers Squibb.

Citation:

Naumann RW et al. J Clin Onc. 2019 Sep 5. doi: 10.1200JCP.19.00739

This Week's Must Reads

Younger adults present with more advanced esophageal adenocarcinoma,

PDAC: Tumor reduction after neoadjuvant therapy may predict postsurgical survival,

Mortality risks rise with age, infections, but not inhibitor status in persons with non-severe hemophilia A,

‘Impressive’ local control with MRI-guided brachytherapy in cervical cancer,

U.S. mothers underestimate role breastfeeding plays in curbing breast cancer,

Must Reads in Gynecologic Cancer

‘Impressive’ local control with MRI-guided brachytherapy in cervical cancer,

Is diagnostic hysteroscopy safe in patients with type 2 endometrial cancer?,

Cervical cancer recurrence patterns differ after laparoscopic and open hysterectomy,

Immune checkpoint inhibitors don’t increase COVID-19 incidence or mortality, studies suggest,

Half of women treated for gynecologic cancers miss or skip doses of oral drugs,